Table 1 Demographic, clinical, histological, immunological, inflammatory features and outcome measures of Chinese primary Sjögren’s syndrome patients with or without neurological involvement
From: Clinical features and risk factors of neurological involvement in Sjögren’s syndrome
Without NP involvement | With NP involvement | P value | |
|---|---|---|---|
290 | 125 | ||
Age (years) | 51.50 ± 13.73 | 52.81 ± 14.95 | 0.387 |
Sex, female, n (%) | 28 (9.66%) | 16 (12.80%) | 0.34 |
Disease duration (months) | 3.99 ± 6.01 | 4.30 ± 5.57 | 0.642 |
Hypertension, n (%) | 57 (19.66%) | 29 (23.20%) | 0.414 |
Diabetes mellitus, n (%) | 22 (7.59%) | 12 (9.60%) | 0.493 |
Hyperlipemia, n (%) | 114 (39.31%) | 37 (29.60%) | 0.059 |
Xerostomia, n (%) | 237 (81.72%) | 88 (70.40%) | 0.010 |
Xerophthalmia, n (%) | 80 (27.59%) | 44 (35.20%) | 0.120 |
ESSDAI | 6.60 ± 2.22 | 8.81 ± 3.45 | < 0.001 |
ESSPRI | 2.87 ± 1.51 | 2.97 ± 1.46 | 0.459 |
Constitutional domain involvement | 65 (22.41%) | 42 (33.60%) | 0.017 |
Glandular domain involvement | 189 (65.17%) | 47 (37.60%) | < 0.001 |
Cardiac involvement, n (%) | 133 (45.86%) | 77 (61.60%) | 0.003 |
LSGB, Lymphocytic focus ≥ 1 | 192 (66.21%) | 76 (60.80%) | 0.291 |
ANA positivity, n (%) | 254 (87.59%) | 120 (96.00%) | 0.008 |
Anti-SSA/Ro60 positive, n (%) | 214 (75.09%) | 97 (78.23%) | 0.494 |
Anti-Ro52 positive, n (%) | 177 (62.11%) | 79 (63.20%) | 0.833 |
Anti-SSB positive, n (%) | 134 (47.02%) | 50 (40.00%) | 0.188 |
Hypergammaglobulinemia (> 16 g/L), n | 186 (64.14%) | 120 (100.00%) | < 0.001 |
Low C3 level (< 0.9 g/L) | 90 (31.03%) | 54 (46.15%) | 0.004 |
Low C4 level (< 0.1 g/L) | 11 (4.17%) | 6 (5.31%) | 0.624 |
RF positive, n (%) | 178 (61.38%) | 59 (52.21%) | 0.093 |
ESR (mm/h) | 35.71 ± 23.84 | 32.43 ± 25.31 | 0.232 |
CRP (mg/L) | 10.23 ± 21.68 | 12.76 ± 24.51 | 0.325 |
Glucocorticoid use | 171 (58.97%) | 81 (66.39%) | 0.158 |
Moderate to high dose | 46 (15.86%) | 24 (19.20%) | 0.405 |
Continuous use for > 1 year | 81 (27.93%) | 38 (30.40%) | 0.610 |